Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Average Recommendation of “Hold” from Analysts

Share on StockTwits

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have received a consensus recommendation of “Hold” from the thirteen analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $15.06.

A number of analysts have recently weighed in on the company. BidaskClub cut Ironwood Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday. ValuEngine upgraded Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. HC Wainwright set a $13.00 price target on Ironwood Pharmaceuticals and gave the stock a “hold” rating in a research report on Monday, June 24th. Wedbush increased their price target on Ironwood Pharmaceuticals from $11.00 to $12.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Finally, Credit Suisse Group reiterated a “neutral” rating on shares of Ironwood Pharmaceuticals in a research report on Wednesday, July 10th.

In related news, President Thomas A. Mccourt sold 220,000 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $9.24, for a total value of $2,032,800.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Halley E. Gilbert sold 20,000 shares of the stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $10.00, for a total value of $200,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 240,212 shares of company stock worth $2,234,716 over the last quarter. Insiders own 5.90% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. United Services Automobile Association grew its holdings in Ironwood Pharmaceuticals by 3.9% in the 2nd quarter. United Services Automobile Association now owns 225,058 shares of the biotechnology company’s stock worth $2,462,000 after buying an additional 8,500 shares in the last quarter. ClariVest Asset Management LLC bought a new position in Ironwood Pharmaceuticals in the 2nd quarter worth approximately $1,455,000. Nuveen Asset Management LLC bought a new position in Ironwood Pharmaceuticals in the 2nd quarter worth approximately $10,126,000. AQR Capital Management LLC grew its holdings in Ironwood Pharmaceuticals by 181.9% in the 2nd quarter. AQR Capital Management LLC now owns 149,888 shares of the biotechnology company’s stock worth $1,640,000 after buying an additional 96,719 shares in the last quarter. Finally, EcoR1 Capital LLC grew its holdings in Ironwood Pharmaceuticals by 6.2% in the 2nd quarter. EcoR1 Capital LLC now owns 4,671,408 shares of the biotechnology company’s stock worth $51,105,000 after buying an additional 274,240 shares in the last quarter.

NASDAQ IRWD traded down $0.05 on Friday, hitting $9.60. 2,540,400 shares of the stock traded hands, compared to its average volume of 1,851,725. The stock has a 50-day moving average of $9.45 and a 200 day moving average of $11.17. Ironwood Pharmaceuticals has a twelve month low of $8.40 and a twelve month high of $19.36. The company has a market capitalization of $1.51 billion, a P/E ratio of -10.11 and a beta of 1.79.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.07) by $0.15. The firm had revenue of $102.22 million for the quarter, compared to analyst estimates of $89.28 million. During the same quarter in the previous year, the company earned ($0.22) EPS. The company’s quarterly revenue was up 26.0% compared to the same quarter last year. Research analysts expect that Ironwood Pharmaceuticals will post 0.01 earnings per share for the current year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.

Read More: What is meant by buying and selling pressure?

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.